Clinical Trial Update: Anti-angiogenesis Agent AG-013736 in Patients With Advanced Non-Small Cell Lung Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial update of anti-angiogenesis agent AG-013736 (cediranib) in advanced non-small cell lung cancer, with the study completed and results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• AG-013736

Snippet

Sponsor: Pfizer | Conditions: Lung Neoplasms, Carcinoma, Non-small Cell Lung | Phase 2 | Status: COMPLETED | Results posted: 2012-03-16